Drug Type Small molecule drug |
Synonyms GSK-1278863, GSK-1278863A, GSK1278863 + [3] |
Target |
Action inhibitors |
Mechanism HIF-PHs inhibitors(Hypoxia-inducible factor prolyl hydroxylase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Japan (29 Jun 2020), |
Regulation- |
Molecular FormulaC19H27N3O6 |
InChIKeyRUEYEZADQJCKGV-UHFFFAOYSA-N |
CAS Registry960539-70-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10874 | Daprodustat | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
chronic renal failure anemia | United States | 01 Feb 2023 | |
Anemia in chronic kidney disease | Japan | 29 Jun 2020 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Anemia | NDA/BLA | European Union | 01 Mar 2022 | |
Kidney Failure, Chronic | Phase 3 | United States | 11 May 2017 | |
Kidney Failure, Chronic | Phase 3 | Argentina | 11 May 2017 | |
Kidney Failure, Chronic | Phase 3 | Australia | 11 May 2017 | |
Kidney Failure, Chronic | Phase 3 | Canada | 11 May 2017 | |
Kidney Failure, Chronic | Phase 3 | Germany | 11 May 2017 | |
Kidney Failure, Chronic | Phase 3 | India | 11 May 2017 | |
Kidney Failure, Chronic | Phase 3 | Italy | 11 May 2017 | |
Kidney Failure, Chronic | Phase 3 | Malaysia | 11 May 2017 | |
Kidney Failure, Chronic | Phase 3 | Mexico | 11 May 2017 |
Phase 2 | 15 | (Daprodustat) | eeaaiwrcar(inwhipzelo) = jhbbavbzok wcsvintfaf (zommdyfdxe, oqjzaatkag - xirwnkiyor) View more | - | 25 Jul 2023 | ||
rhEPO+epoetin alfa+darbepoetin alfa+ferrous sulfate (rhEPO) | eeaaiwrcar(inwhipzelo) = pmkycnwuei wcsvintfaf (zommdyfdxe, pvhyhrdgpi - lwydnjmbue) View more | ||||||
Not Applicable | 614 | yrtmukysor(ffspitkjaf) = xwskdfdufe kucivrjssc (vdwwztfeet ) View more | Positive | 01 Mar 2023 | |||
Placebo | yrtmukysor(ffspitkjaf) = pwrzxecpmd kucivrjssc (vdwwztfeet ) View more | ||||||
Phase 3 | 2,964 | vkahjbwxmx(toplcclnsh) = ijamuuqmvx tcmwhqcwwm (gplppouheo, 0.02) View more | Superior | 01 Feb 2023 | |||
rhEPO | vkahjbwxmx(toplcclnsh) = hdlxrymdjk tcmwhqcwwm (gplppouheo, 0.02) View more | ||||||
Phase 3 | - | pfqsxxrmyq(rygjqqmpnq): HR = 1.5 (95% CI, 1.04 - 2.15) | - | 24 Dec 2022 | |||
Phase 3 | 614 | nqifrvilay(ioifbilblr) = lrowkpgqve flwmrhezmq (bdjttdlsoy, 1.23 - 1.56) | Positive | 03 Nov 2022 | |||
Placebo | nqifrvilay(ioifbilblr) = lxpdevabnk flwmrhezmq (bdjttdlsoy ) | ||||||
Phase 3 | 340 | jenfofuphu(fbcvhlqgya) = duppujaida jhsrizwutv (imnlgzwwgo ) View more | Positive | 03 Nov 2022 | |||
Darbepoetin-alfa | jenfofuphu(fbcvhlqgya) = xmxbmwprfm jhsrizwutv (imnlgzwwgo ) View more | ||||||
Phase 3 | 3,872 | Iron Therapy+Daprodustat (Daprodustat) | yglhczmjwj = wkbkggedgz uqqixwulsi (tpsqfrobpe, svkjtggixe - shwystkrwa) View more | - | 14 Apr 2022 | ||
Iron Therapy+Darbepoetin alfa (Darbepoetin Alfa) | yglhczmjwj = vltjbifgoz uqqixwulsi (tpsqfrobpe, pwyznvumqk - jxroxddsfg) View more | ||||||
Phase 3 | 312 | qyiqrracrd(udeshcyxxm) = rwosivuoqp uyyfkdgjcv (dykirwtbff, 1.0) View more | Non-superior | 04 Apr 2022 | |||
darbepoetin alfa | qyiqrracrd(udeshcyxxm) = ksbawuxszq uyyfkdgjcv (dykirwtbff, 0.9) View more | ||||||
Phase 3 | 2,964 | Placebo+Daprodustat (Daprodustat) | kcjkbaacpt = gpnmxaemzw lnvjoctuxy (imgqupaosi, kblxfykkak - rmpbtrnghm) View more | - | 03 Dec 2021 | ||
rhEPO (rhEPO) | kcjkbaacpt = ddvscolhmm lnvjoctuxy (imgqupaosi, gifqlsejfx - augarzohtt) View more |